Figure 3. Requirements for host irradiation and donor T cells in transplants.

A, Survival of BALB/c hosts that received either 800 cGy TBI (n=5), 450 cGy TBI (n=5) or no conditioning (n=5) before transplantation. p<0.05 for 800cGy vs 450cGy and p<0.0001 for 800 cGy vs 0cGy.

B, Rag 2^−/− BALB/c hosts received transplants after either 800 cGy TBI (n=5) or no irradiation (n=5). p=0.001 for irradiated RAG2^−/− vs unirradiated. C, BALB/c hosts received transplants from BALB/c IFN-γ^−/− donors (n=10)(p=0.004), DBA/2J donors (n=5)(p<0.001) or BALB/c donors vaccinated with either AH-1 peptide and CpG (n=6)(p<0.0001) or irradiated tumor cells and lipopolysaccharide (LPS) instead of CpG (n=5) (p=1.0). (Survival compared with 90 day CpG group from Figure 1E). D, Hosts were given either donor whole bone marrow cells (n=5), or c-kit⁺Sca-1⁺ HSCs alone (n=5), or HSCs and purified splenic T cells (n=6) (p=0.008). E, Hosts received HSCs with either CD4⁺ (n=10) or CD8⁺ (n=8) T cells, or transplants containing a mixture of CD4⁺ and CD8⁺ T cells (n=5) (p<0.008). F, Survival of C57BL/6 mice with MC38 subcutaneous colon tumor nodules given TBI and transplants from C57BL/6 donors that had been vaccinated with irradiated MC38 tumor cells and CpG (n=10) as compared with untreated control mice (n=5). (p<0.008). G, Survival of hosts (n=5) with large subcutaneous tumors established for 15 days after HCT from vaccinated donors compared with survival of untreated animals (p=0.0005).